



COMPANY OVERVIEW

Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.

RECENT NEWS

Coeptis Pharma Enters into Agreement to Acquire Elto Pharma

Nov 28 2018, 7:55 AM EST

Amarantus Provides Corporate Update

Jul 20 2018, 8:17 AM EDT

MANF Therapeutics Announces Positive MANF Pre-Clinical Data in Alpha-Synuclein Model of Parkinson's Disease Published in Peer-Reviewed Journal Experimental Neurobiology

Jul 9 2018, 8:00 AM EDT

STOCK OVERVIEW

Symbol	AMBS
Exchange	OTCPink
Shares OS	68,272,000
Market Cap	\$1.48M
Last Price	\$0.02168
52-Week Range	\$0.018 - \$0.2085
Fiscal Year End	December 31

12/14/2018 03:58 PM
EST

INVESTOR RELATIONS

American Capital Ventures, Inc.
Howard Gostfrand
President
T: 305-918-7000
F: 305-468-6165
hg@amcapventures.com

MANAGEMENT TEAM

Gerald E. Commissiong

President & Chief Executive Officer

Barney Monte

Interim Chief Operating Officer and Chief Financial Officer

Brian E. Harvey, MD, PhD

Chief Regulatory Advisor

Elise Brownell, Ph.D.

Senior Vice President of Operations and Project Management

John W. Commissiong, PhD

Chief Scientific Officer

Paula Trzepacz, MD

Chief Medical Advisor to Elto Pharma

Dr. Richard Kagan

Chief Medical Advisor to Cutanogen Corporation

Michael T. Ropacki, PhD

Chief Medical Advisor - Alzheimer's Blood Diagnostic LymPro Test®

AMARANTUS BIOSCIENCE HOLDINGS, INC.

110 Wall Street
New York, NY 10005
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.